Stevanato Group, CEPI Ink Agreement for 100M Glass Vials for COVID-19 Vaccines
By Contract Pharma Staff | 06.25.20
To supply of 100 million Type 1 Borosilicate glass vials to hold up to 2 billion doses of a COVID-19 vaccine, should product(s) be proven safe and effective.
Through this agreement, Stevanato Group, which produces 10 billion units a year of drug delivery systems, sterile and bulk glass containers, plastic diagnostic and medical components, becomes a key supplier to CEPI’s COVID-19 vaccine programs.
To date, CEPI has worked in coordination with its partners, investing as much as $829 million in nine COVID-19 vaccine candidates. The ultimate goal is to speed up the vaccine development timeframe to develop a successful vaccine in an accelerated 12-18-month timeframe.
The high-quality glass vials that CEPI have secured from Stevanato Group will be able to store 20 doses per vial (2 billion doses in total). The Group will also grant a "fast track" access to its glass vial forming lines provided by its company Spami.